Identification of ATAD3A as a key regulator in non‐small cell lung cancer by promoting STAT3‐induced cell proliferation and tumor angiogenesis
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23667 ↗At a glance
Journal article in Molecular Carcinogenesis, 2024. Written by Tao Jiang and 6 co-authors. Institution: Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang, China. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adenocarcinoma of Lung. Cited 6 times so far (Crossref); 29 references. Funded by: Project of Education Department of Zhejiang Province, Hangzhou Health Science and Technology Project, Jinhua Science and Technology Project.
Abstract (original language)
Malignant proliferation and abundant angiogenesis are major causes of lung adenocarcinoma (LUAD) with high morbidity and mortality. Therefore, the exploration of the key regulatory mechanisms of malignant proliferation and angiogenesis in LUAD provides an opportunity for the development of targeted precision therapy. In this study, we found that the high expression of ATPase family AAA domain‐containing protein 3A (ATAD3A) in LUAD was positively associated with the poor survival of patients, while its high expression was positively associated with the angiogenesis of LUAD. Further knockdown of ATAD3A in LUAD significantly inhibited cell proliferation and suppressed expression of vascular endothelial growth factor A, FGF‐2, ANG‐1, and TGF‐β. The opposite effect was observed with ATAD3A overexpression. Furthermore, ATAD3A knockdown significantly inhibited tumor growth and angiogenesis in an in vivo subcutaneous xenograft tumor model. Mechanistic studies suggest that ATAD3A may promote signal transducer and activator of transcription 3 activation, a key signal regulating lung cancer cell proliferation and transcriptional secretion of proangiogenic factors. Therefore, targeted inhibition of ATAD3A may be an effective strategy for LUAD therapy, and ATAD3A may be a potential biomarker for predicting malignant progression.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang, China.
- Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Respiratory and Critical Care Medicine, The Hospital of Xinjiang Production and Construction Corps, Urumqi, Xinjiang, China.
Funding
- Project of Education Department of Zhejiang Province
- Hangzhou Health Science and Technology Project
- Jinhua Science and Technology Project
Cite
APA
Jiang, T., Li, N., Xu, H., Sun, L., Zhang, Y., Luo, Q., & Yang, L. (2024). Identification of ATAD3A as a key regulator in non‐small cell lung cancer by promoting STAT3‐induced cell proliferation and tumor angiogenesis. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23667
Vancouver
Jiang T, Li N, Xu H, Sun L, Zhang Y, Luo Q, et al. Identification of ATAD3A as a key regulator in non‐small cell lung cancer by promoting STAT3‐induced cell proliferation and tumor angiogenesis. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23667
BibTeX
@article{Jiang2024,
author = {Jiang, Tao and Li, Ning and Xu, Hao and Sun, Li and Zhang, Ying and Luo, Qian and Yang, Li},
title = {Identification of ATAD3A as a key regulator in non‐small cell lung cancer by promoting STAT3‐induced cell proliferation and tumor angiogenesis},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23667}
}
EUVIMED